US2013142801A1PendingUtilityA1

Antibody to human zcyto-10 polypeptide

Assignee: ZYMOGENETICS INCPriority: Nov 26, 1997Filed: Jan 18, 2013Published: Jun 6, 2013
Est. expiryNov 26, 2017(expired)· nominal 20-yr term from priority
A61K 39/3955A61P 43/00C07K 14/52
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Antibodies that which specifically bind to mammalian cytokine-like polypeptide, called Zcyto10, are described. The antibodies include monoclonal antibodies and those that where the antibody is an antigen-binding fragment. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.

Claims

exact text as granted — not AI-modified
1 - 8 . (canceled) 
     
     
         9 . A method of treating a subject diagnosed with a disease of the tracheobronchial tract, comprising administering an antibody, or binding fragment thereof, which binds to Mammalian Cytokine-like polypeptide-10 (Zcyto10) (SEQ ID NO: 2), such that the subject is treated. 
     
     
         10 . The method of  claim 9 , wherein the disease is selected from asthma and bronchitis. 
     
     
         11 . The method of  claim 9 , wherein the antibody is a polyclonal or a monoclonal antibody. 
     
     
         12 . The method of  claim 9 , wherein the fragment is an F(ab′) 2  fragment. 
     
     
         13 . The method of  claim 9 , wherein the fragment is an Fab fragment. 
     
     
         14 . The method of  claim 9 , wherein the antibody or fragment binds to the amino acid residues selected from the group consisting of (a) amino acid residues 25 to 176 of SEQ ID NO:2, (b) amino acid residues 35 to 49 of SEQ ID NO:2, (c) amino acid residues 57 to 71 of SEQ ID NO:2, (d) amino acid residues 91 to 105 of SEQ ID NO:2, (e) amino acid residues 112 to 126 of SEQ ID NO:2, and (f) amino acid residues 158 to 172 of SEQ ID NO:2. 
     
     
         15 . The method of  claim 9 , wherein the antibody or fragment binds to an amino acid sequence selected from the group consisting of (a) SEQ ID NO:12, (b) SEQ ID NO:26, (c) SEQ ID NO:14, (d) SEQ ID NO:15, (e) SEQ ID NO:16, and (f) SEQ ID NO:17. 
     
     
         16 . The method of  claim 9 , wherein the antibody is a monoclonal antibody. 
     
     
         17 . The method of  claim 9 , wherein the disease is asthma. 
     
     
         18 . The method of  claim 9 , wherein the disease is bronchitis.

Join the waitlist — get patent alerts

Track US2013142801A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.